Revenue: $617 million for Q1 2025. Core Growth: 0.2% in Q1 2025. Adjusted EBITDA Margin: Approximately 13% for Q1 2025. Adjusted EPS: $0.24, slightly above expectations. Adjusted Gross Margin: 54.8%, a decrease of 260 basis points year-over-year. Free Cash Flow: Outflow of $5 million in Q1 2025. Net Debt to Adjusted EBITDA: Approximately 1 times. Share Repurchase Program: $19 million worth of stock repurchased in Q1 2025. Currency Exchange Impact: Negative impact of 140 basis points on sales year-over-year. Specialty Products and Technology Segment: Revenue declined by 70 basis points year-over-year. Equipment and Consumables Segment: Core sales increased by 170 basis points year-over-year. Non-GAAP Tax Rate: 31.5% for Q1 2025. Warning! GuruFocus has detected 5 Warning Signs with NVST. Release Date: May 01, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Envista Holdings Corp (NYSE:NVST) delivered core growth of 0.2% and adjusted EBITDA margin around 13%, both in line with expectations. The company reported adjusted EPS of $0.24, slightly ahead of expectations. Progress was made on the $250 million share repurchase program announced previously. Growth was observed across most of the portfolio, including Consumables and Nobel Biocare, with improvements in customer service and Spark margins. Envista Holdings Corp (NYSE:NVST) maintained its 2025 guidance of 1% to 3% core growth, approximately 14% adjusted EBITDA margins, and adjusted EPS of $0.95 to $1.05. Negative Points Currency exchange rates negatively impacted sales year over year by about 140 basis points. The Specialty Products and Technology segment saw a decline of about 1 point. Adjusted gross margin decreased by 260 basis points versus the prior year, primarily due to foreign exchange rates. Free cash flow was an outflow of $5 million in Q1, attributed to the timing of incentive compensation and working capital. The global dental market remains stable but faces geopolitical uncertainties and deteriorating US consumer confidence indices. Q & A Highlights Q: Can you elaborate on your current tariff exposure and the steps you're taking to mitigate the impact? A: Paul Keel, President and CEO, explained that the main tariff exposure areas are US goods imported into China and Chinese goods imported into the US. To mitigate this, Envista is shifting some of its China supply from the US to Sweden and expects suppliers to manage tariff impacts themselves. Additionally, Envista is qualifying new suppliers to enhance supply chain resilience. Story Continues Q: What are the April trends in terms of volume and conversion to higher ASP procedures like implants and clear aligners? A: Paul Keel noted that the macro market trends in April were similar to Q1, with no significant shifts in procedure types. April started well, and there were no major changes in consumer behavior towards higher ASP procedures. Q: Can you provide more details on the gross and net impacts of tariffs on your business this year? A: Paul Keel stated that the guidance includes current tariff activities, and they are confident in mitigating these impacts in the second half of the year. The expected outcome remains the same as initially guided, despite wider error bars due to macro uncertainties. Q: What are your expectations for VBP (Volume-Based Procurement) in China this year, and how is it reflected in your guidance? A: Paul Keel mentioned that the ortho VBP is progressing as expected, with procedure cost VBP underway and supply cost VBP to follow. The guidance anticipates a soft first half in Brackets and Wires in China, with benefits expected in the second half. Q: How are you managing pricing power in a tariff environment, and what is your strategy for capturing price increases? A: Paul Keel explained that pricing power varies by country, category, and customer type. Innovation-driven products can capture higher prices, while commodity products are more price-sensitive. The US market is currently more price-sensitive compared to other regions. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. View Comments
Envista Holdings Corp (NVST) Q1 2025 Earnings Call Highlights: Navigating Challenges with ...
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...